Anti-ERBB3/ HER3 Reference Antibody (Patritumab deruxtecan) is a novel ADC composed of an anti-HER3 antibody (Patritumab) and a novel potent topoisomerase I inhibitor DX-8951,conjugated, on an average of 8 cysteinyl, to deruxtecan, comprising a linker an